Diagnosis, Treatment and Prognosis of Mesonephric Adenocarcinoma of the Vagina: A Literature Review and a Case Report.
gynecologic oncology
mesonephric adenocarcinoma
minimally invasive surgery
rare neoplasm
vaginal cancer
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
23 Jul 2023
23 Jul 2023
Historique:
received:
28
05
2023
revised:
13
07
2023
accepted:
20
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Mesonephric adenocarcinoma (MA) of the vagina is a rare tumor that arises from mesonephric remnants (Wolffian) in the female genital tract. It is a neoplasm with no significant evidence about its diagnosis, treatment, follow-up and prognosis. Systematic research of the literature was conducted in Scopus, PubMed/MEDLINE, ScienceDirect and the Cochrane Library, including observational prospective and retrospective studies, case series and case reports. We collected data regarding studies related to diagnosis and treatment options evaluating the following aspects: study design, population, treatment type, rate of surgical complications and fertility outcome. We further included a case report of laparoscopic management of MA with pictorial assays. Thirteen cases of MA of the vagina are available in the literature, including our case report. The median age at diagnosis was 52 years old; the majority of patients reported vaginal bleeding as a symptom (38%); and ultrasound, followed by a magnetic resonance and CT scan were the diagnostic tools most used. In 54% of the cases, a surgical biopsy was performed, and 92% of the patients underwent upfront surgery with an open access or vaginal resection except one case fully managed by minimally invasive surgery. Most of the patients (68%) received adjuvant treatment with chemotherapy or radiotherapy or a combination of them. The mean follow-up period was 6 years. Despite the rarity of this cancer and bizarre location, a minimally invasive approach seems feasible after multidisciplinary evaluation. According to the rarity of this tumor, any future case and follow-up data must be reported in the literature in order to enlarge the knowledge about it.
Sections du résumé
BACKGROUND
BACKGROUND
Mesonephric adenocarcinoma (MA) of the vagina is a rare tumor that arises from mesonephric remnants (Wolffian) in the female genital tract. It is a neoplasm with no significant evidence about its diagnosis, treatment, follow-up and prognosis.
METHODS
METHODS
Systematic research of the literature was conducted in Scopus, PubMed/MEDLINE, ScienceDirect and the Cochrane Library, including observational prospective and retrospective studies, case series and case reports. We collected data regarding studies related to diagnosis and treatment options evaluating the following aspects: study design, population, treatment type, rate of surgical complications and fertility outcome. We further included a case report of laparoscopic management of MA with pictorial assays.
RESULTS
RESULTS
Thirteen cases of MA of the vagina are available in the literature, including our case report. The median age at diagnosis was 52 years old; the majority of patients reported vaginal bleeding as a symptom (38%); and ultrasound, followed by a magnetic resonance and CT scan were the diagnostic tools most used. In 54% of the cases, a surgical biopsy was performed, and 92% of the patients underwent upfront surgery with an open access or vaginal resection except one case fully managed by minimally invasive surgery. Most of the patients (68%) received adjuvant treatment with chemotherapy or radiotherapy or a combination of them. The mean follow-up period was 6 years.
CONCLUSIONS
CONCLUSIONS
Despite the rarity of this cancer and bizarre location, a minimally invasive approach seems feasible after multidisciplinary evaluation. According to the rarity of this tumor, any future case and follow-up data must be reported in the literature in order to enlarge the knowledge about it.
Identifiants
pubmed: 37510961
pii: jcm12144846
doi: 10.3390/jcm12144846
pmc: PMC10381470
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1:19-27
pubmed: 34669198
Am J Surg Pathol. 2004 May;28(5):601-7
pubmed: 15105647
Nihon Hinyokika Gakkai Zasshi. 1983 Dec;74(12):2148-53
pubmed: 6677796
Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1127-31
pubmed: 18028380
Int J Gynecol Pathol. 2014 Nov;33(6):624-9
pubmed: 25272303
Pathology. 2018 Feb;50(2):141-150
pubmed: 29269124
Acta Obstet Gynecol Scand. 1955;34(1):120-30
pubmed: 14398162
Strahlenther Onkol. 2016 Sep;192(9):668-71
pubmed: 27349710
Cancer Radiother. 2021 Dec;25(8):816-821
pubmed: 34711486
BMJ Case Rep. 2018 Jul 3;2018:
pubmed: 29970606
J Gynecol Oncol. 2020 Sep;31(5):e71
pubmed: 32808498
Gynecol Oncol. 2005 Dec;99(3):757-60
pubmed: 16137744
J Minim Invasive Gynecol. 2021 Jun;28(6):1137
pubmed: 32911088
Int J Gynecol Cancer. 2009 Dec;19(9):1655-7
pubmed: 19955954
J Cancer Res Ther. 2022 Jan-Mar;18(1):277-279
pubmed: 35381800
Nihon Hinyokika Gakkai Zasshi. 1985 Jan;76(1):104-9
pubmed: 4010108
Diagnostics (Basel). 2022 Jan 05;12(1):
pubmed: 35054285
Curr Opin Obstet Gynecol. 2015 Aug;27(4):291-6
pubmed: 26107782
Medicine (Baltimore). 2021 Sep 3;100(35):e27174
pubmed: 34477176
Pan Afr Med J. 2015 Jun 15;21:126
pubmed: 26327963
Cancer. 1978 Jul;42(1):214-23
pubmed: 208750
Wien Klin Wochenschr. 1977 Apr 29;89(9):313-5
pubmed: 857437
Gynecol Oncol Rep. 2020 Sep 26;34:100652
pubmed: 33024807
Eur J Gynaecol Oncol. 2017;38(1):157-161
pubmed: 29767889
World J Surg Oncol. 2013 Jun 03;11:126
pubmed: 23725440